The second Phase I clinical trial is a dose-escalation study in patients with multiple myeloma. This clinical study will assess the safety, toxicity, and maximum tolerated dose of NPI-0052 when administered intravenously. Subsequent to determining the maximum tolerated dose, 12 additional patients will be entered to gain preliminary data on efficacy. Dependent on the degree of efficacy seen in this trial, Nereus expects to pursue an accelerated registration strategy in multiple myeloma.

To learn more about these clinical trials please visit www.clinicaltrials.gov .

• Nereus Pharmaceutical drugs are in preclinical or clinical trail testing, and are not available by prescription from doctors. Patients can only receive these drugs if they are participating in a sponsored clinical trial.
• If you are a patient and interested in entering a clinical trial, it is best that you consult your doctor regarding appropriate and available treatments for your condition, and whether or not you should enter a clinical trial. Your physician can find a description and list of participating centers for clinical trials sponsored by Nereus Pharmaceuticals, as well as other clinical trials for patients with cancer, at www.clinicaltrials.gov.
• Nereus pharmaceuticals cannot respond to patient inquiries on medical matters.
• Clinical trials can only be entered by contacting participating physicians and centers. Patients cannot enter clinical trials by contacting Nereus Pharmaceuticals.